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/3 1-Adrenergic receptors in kidney tubular cell membrane in
the rat. We used a beta-adrenergic antagonist, (—) 'H-dihy-
droalprenolol, to demonstrate binding sites in purified rat
kidney preparations that consisted of plasma membranes
of cells from tubules. The tubular origin of these plasma
membranes was shown by electron microscopy and Na-K-
ATPase enrichment. The binding was rapid (tV2, 78 see) and rap-
idly reversible (t'/2, 48 sec). The binding sites were saturable and
bound 69.8 (so) 29.1 fmoles/mg of membrane protein. The
binding was stereospecific with the isomers of beta-adrenergic
agonists and beta-adrenergic antagonist propranolol, the (—)
isomers being about 40 times more potent than the (+) iso-
mers in competing for these sites. (—) H-dihydroalpt-enolol
had a high affinity for the binding sites, expressed by the
mean equilibrium dissociation constant (KD) (KD, 7.1 nM). The
beta-adrenergic antagonist (—) propranolol also showed high
affinity(KD, 62.8 nM). The order of potency for inhibition of bind-
ing by beta-adrenergic agonists was: (—) isoproterenol (KD, 0.66
M) > (—) epinephrine (KD, 4.3 )  (—) norepinephrine (KD,
13.5 SM). Conclusion. The (—) 3H-dihydroalprenolol binding
sites in the rat kidney tubular cell membrane are beta-adrenergic
receptors of the /3, subgroup.
Récepteurs /3,-adrénergiques dans les membranes cellulaires des
tubes rénaux du rat. L'antagoniste béta-adrénergique, (—) 'H-
dihydroalprenolol, a été utilisé pour mettre en evidence les sites
de liaison dans une preparation purifiée de rein de rat constituée
de membranes cellulaires tubulaires. L'origine tubulaire de ces
membranes plasmiques a été démontrée par Ia microscopie élec-
tronique et l'enrichissement en Na-K-ATPase. La liaison est rap-
ide (t'/2, 78 sec) et rapidement reversible (t'/2, 48 see). Les sites
de liaison sont saturables et lient 69,8 (so) 29,1 fmoles/mg de
protéines membranaires. La liaison est stéréospécifique avec les
isomères des agonistes béta-adrénergiques et de l'antagoniste
béta-adrénergique propranolol. Les isomères (—) sont environ
40 fois moms puissants que les isomères (+) dans Ia competition
pour ces sites. (—) 'H-dihydroalprenolol a une affinité élevée
pour les sites de liaison (KD, 7,1 nM). L'antagoniste béta-adré-
nergique (—) propranolol a aussi une haute afilnité (KD, 62,8 nM).
L'ordre décroissant de puissance d'inhibition de Ia liaison des
agoniste béta-adrénergiques est: (—) isoproterenol (K,,, 0,66 tLM)
> (—) épinéphrine (KD, 4,3 pvt)  (—) norépinéphrine (K,,, 13,5
ILM). Conclusion. Les sites de liaison (—) 'H-dihydroalprenolol
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dans les membranes cellulaires de tube renal de rat sont les ré-
cepteurs béta-adrenergiques du sous groupe /3g.
The effect of the sympathetic nervous system on
renal hemodynamics and renin release suggests that
the beta-adrenergic receptors in the kidney may be
located in the cortical region, namely in the jux-
taglomerular apparatus and in the vascular pole of
the glomerulus. The i.v. administration of the fluo-
rescent beta-adrenergic antagonist 9-amino-acri-
dine propranolol in the rat showed fluorescent ag-
gregates in these areas [1]. Also, indirect evidence
for the existence of beta-adrenergic receptors in
renal tubular cells is available. Electron microscop-
ic and histochemical studies showed evidence for
adrenergic nerve fibers in the cortical tubules of the
monkey [2]. The use of the fluorescent beta-adren-
ergic antagonist also showed binding along the renal
collecting system [I], though the authors were un-
certain as to whether this represented specific bind-
ing or was the result of the large renal secretion of
the fluorescent compound.
Direct binding of radioisotope-labeled beta-ad-
renergic antagonists to membrane proteins was
used to demonstrate the presence of beta-adrener-
gic receptors in various mammalian tissues [3—6],
avian [7-9], and frog erythrocytes [10]. These
chemically labeled sites fulfilled binding criteria of
affinity and stereospecifIcity, which correlated high-
ly to the adenylate cyclase activation by beta-adren-
ergic drugs [3—10].
In the present study, we attempt to demonstrate
the presence of beta-adrenergic receptors in the rat
kidney tubular cell membranes by the direct bind-
ing of the beta-adrenergic antagonist () :q..
dihydroalprenolol (3H-DHA) [3, 10—13]. The rel-
ative potencies of isoproterenol, epinephrine, and
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Fig. 1. Electron micrograph of the x 35,000 g max fraction showing membrane vesicles of various sizes. The arrow shows a fragment
which is reminiscent of a brush border microvillus. (x36,000)
norepinephrine in their ability to inhibit this bind-
ing, were used to characterize these beta receptors
as belonging to the /3 subgroup.
Methods
Drugs. 3H-DHA (specific activity, 58.5 Cilmmole)
was used (prepared by New England Nuclear) and
stored at —20° C. Other compounds used were: (—)
propranolol hydrochloride and (+) propranolol hy-
drochloride (ICI), (—) isoproterenol-D-bitartarate,
(—) epinephrine-bitartarate, (—) norepinephrine-bi-
tartarate (Sigma), (+) isoproterenol-D-bitartarate,
(+) epinephrine-L-bitartarate (Winthrop).
Membrane preparation. Rat renal tubular cell
plasma membranes were prepared according to the
method of Fitzpatrick et al [14]. Charles River rats
of either sex, weighing 250—350 g were used. The
kidneys were removed, with the rats under ether
anesthesia, and placed immediately in ice-cold iso-
tonic sucrose buffer (0.25 M sucrose, 1 mrvi EDTA).
All subsequent steps were carried out at 0 to 2° C.
The kidneys were homogenized with a Potter ho-
mogenizer in the isotonic sucrose buffer (three vol-
umes). The gauze-filtered homogenate was centri-
fuged for 10 mm at x 1475g (maximum). The sedi-
mented material, which contained cell debris,
nuclei, large membrane fragments, and mito-
chondria, was resuspended in 2 M sucrose (1 ml!g of
original tissue) and centrifuged for 10 mm at
x 13,300g (maximum). This centrifugation sedi-
mented nuclei and cell debris. The supernatant con-
taining membranes and mitochondria was diluted to
isotonicity by the addition of seven volumes of ice-
cold distilled water. The suspension was centri-
fuged for 15 mm at x35,000g (maximum). The re-
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suiting pellet consisted of two distinct layers: a
lower brown pellet of mitochondria and an upper
pink layer of membranes. The upper layer was re-
moved by swirling isotonic sucrose over the pellet.
The x 35,000g centrifugation and the following re-
suspension were repeated three more times, with
incubation buffer (Tris, 75 m; magnesium chlo-
ride, 25 mM; pH, 7.4 at 37° C) for the last wash. The
final pellet, which contained tubular cell plasma
membranes, was resuspended in 1 ml of incubation
buffer for each 2 g of original tissue, divided into
one-assay aliquots, and stored in liquid nitrogen.
Neither freezing nor prolonged storage in liquid ni-
trogen altered the binding characteristics of the
membranes.
Na-K-ATPase activity enrichment and electron
microscopy were used as evidence for the purity of
the tubular cell plasma membrane preparation.
Electron microscopy. The x35,000g pellet was
fixed in 3% glutaraldehyde in 0.1 M cacodylate buf-
fer (pH 7.4) for 2 hours, rinsed in the same buffer,
and postfixed in 1% osmium tetroxide in 0.2 M Ca-
codylate buffer (pH, 7.4). It was dehydrated and
embedded in Epon 812. Thin sections were cut with
a diamond knife and stained with uranyl acetate and
lead citrate. Sections were examined with an elec-
tron microscope (Philips EM300). The electron mi-
crograph showed membrane vesicles and frag-
ments that were reminiscent of microvilli of the
tubular brush border (Fig. I).
Na-K-A TPase activity enrichment. This determi-
nation was based on a procedure described by Jor-
gensen [15]. Prior to the assay, particulate mem-
brane material was incubated with sodium deoxy-
cholate (DO C) at 00 C for 20 mm (500 tg of protein!
ml of mixture containing 2.4 mi DOC, 3 m ED-
TA, 33.3 mt Tris hydrochloride buffer; pH, 7.4 at 37°
C). For the assay, the protein was diluted with 33.3
mM Tris hydrochloride buffer to the concentration
of 10 to 30 j.g per 0.1 ml. The reaction volume was
0.5 ml. For magnesium-dependent ATPase activity,
0.1 ml of diluted protein was incubated with 4 mt
magnesium chloride, 5 mrvi sodium azide, 0.5 mri
EGTA, 3.4 mi ATP, and 1 m ouabain. For total
ATPase activity, 110 ifiM sodium chloride and 15
m potassium chloride were added, and ouabain
was substituted by water. The reaction mixture was
incubated at 37° C for 20 mm. The incubation was
terminated by immersion in an ice bath. Aliquots
were taken into ice-cold ferrous trichloracetic acid
reagent, and inorganic phosphorus (Pi) was deter-
mined by the method of Fiske and Subbarow [16].
The Na-K-ATPase activity was calculated by
subtracting the magnesium-dependent ATPase ac-
tivity from the total ATPase activity. The reaction
was linear with respect to time and concentration
until about 20% of the total ATP present (3.4 mM)
was split. The purified membrane fraction showed a
3.5-fold increase (from 15 to 53 j.mo1es of Pilmg of
protein!hr) in the Na-K-ATPase specific activity as
compared with the original crude nuclear fraction.
Binding assay. Prior to the binding assay [3, 5],
the membranes were thawed at 00 C, diluted with
incubation buffer to a protein concentration of 5 mg/
ml, and sodium metabisulfite was added (40 pg/mg
of membrane protein) [7]. The protein concentra-
tion was measured by the method of Lowry et at
[17].
Dihydroalprenolol (DHA) binding was assayed
by incubating 500 pg of membrane protein (con-
tained in 100 l) with 25 zl of 3H-DHA (2 to 20 nM
final concentration) and 25 jl of water or com-
petitive drug in logarithmically increasing concen-
trations. Both the 3H-DHA and the competitive
drug were diluted in distilled water on the day of the
assay. The membranes were added to the reaction
mixture at the beginning of the incubation. The mix-
ture was incubated for 10 mm at 37° C in a shaking-
water bath. Incubation was stopped by diluting the
mixture with 20 volumes (3 ml) of ice-cold in-
cubation buffer and rapid (3 sec) vacuum filtering
through a Whatman GF!C glass-fiber filter (Linca's
Multiple Membrane Filter, Lamon Instrumentation
Co, Tel-Aviv, Israel). Each filter was washed with
eight additional 3 ml portions of ice-cold incubation
buffer. The filters were counted by liquid scintilla-
tion spectrometry in 3.5 ml of dioxane-based scintil-
lation cocktail at 36% efficiency. The binding exper-
iments were done in triplicates, and the nonspecific
binding to membranes was determined by measur-
ing the amount of radioactivity retained on filters
when incubations were performed in the presence
of 5 mri (—) propranolol hydrochloride. This value
was subtracted from the total bound to determine
specific binding. Binding experiments were also
performed in the presence of 5 LM (—) propranolol
hydrochloride.
Results
Binding kinetics. The time course of (—)3H-DHA
binding was determined by incubating 500 j.g of
membrane protein with 10 flM of DHA for various
periods of time (Fig. 2). The half-time (t'/2) for asso-
ciation was 78 sec, and the equilibrium was reached
after 6 mm. The reversibility of the binding was evi-
denced by the rapid dissociation of (—) 3H-DHA
from the membranes following the addition of 5 mM
(—) propranolol hydrochloride to the equilibrated
mixture. Fifty percent of the specific bound (—) 3H-
DHA dissociated within 48 sec.
1 2 3 4 5 6 7 8 9 10 111213 14 15 1617 18 19 2021 22232425
Time, rn/n
Fig. 2. Time-course of association and dissociation of(—)3H-DHA specific binding to tubular cell membranes. At the arrow, (—)propran-
olol was added to the equilibrated incubation mixture containing membranes and (—)3H-DHA. The curves represent the mean of two
experiments.
2 4 6 8 10 12 14 16 18 20
(—)3H-DHA,MX1O
Fig. 3. Saturability of specific (—)3H-DHA binding sites. The ex-
periment shown is representative of ten such experiments.
Saturability and affinity. We incubated 500 p.g of
membrane protein with increasing amounts of 3H-
DHA. Of the total (—) 3H-DHA bound, 80 to 90%
were displaced by the addition of 5 mM (—)propran-
olol hydrochloride. The undisplaceable fraction,
that is, the nonspecific binding, increased linearly
with increasing concentrations of 3H-DHA. The dis-
placeable fraction, being the specific binding, was
saturable (Fig. 3). Decreasing the wash volume
from 27 to 12 ml [5] resulted in a small decrease in
percent specifically bound alprenolol out of the total
bound (from 80 to 70%). The amount of specifically
bound alprenolol did not change significantly (50.3
4.5 fmoles/mg of protein, N = 7 vs. 53.8 2.7
fmoles/mg of protein, N = 8). Scatchard analysis of
binding experiments (Fig. 4) indicated the presence
of a single population of binding sites. The mean
200 400 600 800
I—) 3H-DHA bound, cpm/O.5 rng protein
Fig. 4. Scatchard plot of (—)3H-DHA binding to tubular cell
membranes. B/F refers to the ratio of bound/free labeled DHA at
equilibrium. The line shown was drawn by linear regression anal-
ysis of the data from Fig. 3. The equilibrium dissociation con-
stant (KD) was calculated from the negative reciprocal of the
slope of the line, and the number of sites (B) was calculated from
the intercept of the line with the abscissa.
equilibrium dissociation constant (KD) as measured
from 10 experiments performed on eight different
membrane preparations was 7.1 ni (SD)3.0. The
mean number of sites was 69.8 (SD) 29.1 fmoles/
mg of protein. The binding characteristics were not
affected by decreasing the (—) propranolol hydro-
chloride concentration used to displace the bound
(—) 3H-DHA, from 5 m to 5 M (Fig. 5).
Specificity of binding. The (—) 3H-DHA binding
sites exhibited stereospecificity in binding beta-ad-
renergic agonists and the beta-adrenergic antagonist
propranolol (Figs. 6 to 8). All the drugs used were
tested for their ability to inhibit (—) 3H-DHA bind-
ing to the membrane preparation by incubating log-
arithmically increasing concentrations of each ste-
reoisomer with 500 j.g of membrane protein and 10
nM 3H-DHA. For both propranolol and the agonists
8
8
'K
-oC
0
-o
II
131-Adrenergic receptors in the rat kidney 767
I—) Propranolol, 5 mM
100
90
80
70
60
50
1—
—
I III A I A J I A40302010
Total
1000
900
800
.
B = 66.8 fmoles/mg protein
KD = 4.22 flM
r = —0.938
1.1
x
U-
Nonspecific
0
768 Gavendo et a!
3.2
x
U-
200 400 600
(—I 3H.DHA bound, cpm/U.5 mg protein
Fig. 5. Scatchard plots of parallel (—)3H-DHA binding assays.
Nonspecific binding was determined using 5 mi (— )propranolol
hydrochloride (continuous line) and 5 tst (—)propranolol hydro-
chloride (interrupted line).
8 7 6 5 4 3 2
— log isoproterenol, m
Fig. 6. Dose-response Curves for inhibition of( —)3H-DHA bind-
ing by the (—) and the (+) stereoisomers of the beta adrenergic
agonist isoproterenol. The experiment shown is representative
of three such experiments.
(isoproterenol and epinephrine), the (—) isomers
were about 40 times more potent in inhibiting bind-
ing than were the corresponding (+) isomers (Table
1). The order of potency for inhibition of (—) 3H-
DHA binding by beta-adrenergic agonists was as
follows: (—) isoproterenol (KD, 0.66 /LM) > (—) epi-
nephrine (KD, 4.3 pM)  (—) norepinephrine (KD,
13.5 /.LM) (Table 1 and Fig. 9).
Discussion
The data presented in this study suggest the pres-
ence of adrenergic receptors in the rat kidney mem-
2.4
8 7 6 5 4 3 2
—log epinephrine, M
Fig. 7. Dose-response curves for inhibition of ( —)3H-DHA bind-
ing by the (—) and the (+) stereoisomers of the beta adrenergic
agonist epinephrine. The experiment shown is representative of
three such experiments.
; 6
—log propranolol, M
Fig 8. Dose-response Curves for inhibition of ( —)3H-DHA bind-
ing by the (—) and the (+) stereoiso,ners of the beta adrenergic
antagonist propranolol. The experiment shown is representative
of four such experiments.
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brane preparation. The evidence for the nature of
this preparation is based on the electron microscop-
ic examination [14] as well as on the Na-K-ATPase
enrichment [18]. The cumulative results are consis-
tent with the renal tubular cell origin of the prepara-
tion. The (—) 3H-DHA binding to these membranes
was rapid (t'12, 48 sec). The (—) 5H-DHA binding
sites were saturable, displaying high affinity (KD,
7.1 nM). These data are comparable with values re-
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Table 1. Apparent dissociation constants of beta-adrenergic
agents
Half-maximal inhibition
Adrenergic agonist
or antagonist
of(—)3H-DHA bindingM
(—)Propranolol 0.0628(4)
(—)isoproterenol 0.657 (3)
(+)Propranolol 2.61 (3)
(—)Epinephrine 4.26 (4)
(—)Norepinephrine 13.48 (3)
(+)Isoproterenol 26.47 (3)
(+)Epinephnne 172.5 (2)
a Values are the mean concentrations. Numbers in parentheses
indicate number of experiments.
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Fig. 9. Dose-response curves for the inhibition of (—)3H-DHA
binding by the (—) stereoisomers of the beta adrenergic agonists
isoproterenol, epinephrine and norepinephrine. Each point rep-
resents the mean of three to four different experiments.
ported by other investigators such as: 10 flM in hu-
man leukocytes [5], 11 flM in canine myocardium
[3], 5 flM in frog erythrocytes [10].
The (—)3H-DHA binding sites exhibited stereo-
specificity, the (—) isomers of beta-adrenergic
agents tested being 40 times more potent than the
(+) isomers. The order of relative potencies of beta-
adrenergic agonists suggests that the (—) 5H-DHA
binding sites are of the /3 type. In our experiments,
(—) isoproterenol was six times more potent than
was the (—) epinephrine; whereas (—) epinephrine
and (—) norepinephrine were about equipotent.
These findings are in accordance with the require-
ments for the characterization of the f3 adrenergic
receptors [12, 13, 19—21]: (—) epinephrine and (—)
norepinephrine being equipotent and (—) isopro-
terenol being about five to ten times more potent
than were both the others.
Quantitative and qualitative characterization of
extravascular tubular cell beta-adrenergic receptors
of f3 type may provide a better understanding of
different functions in physiologic and pathologic
conditions. Changes in tubular sodium transport as
a direct effect of the beta-adrenergic system on the
tubules have been reported [22, 23]. Another inter-
esting possibility is the participation of the tubular
beta-adrenergic receptors in the development of is-
chemic acute renal failure. This was suggested by
us [24, 25] based on propranolol's and practolol's
important alleviating effect in experimental anoxic
acute renal failure in rats.
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